In a 2-year clinical trial of relapsing MS patients, 627 people were treated with TYSABRI versus 315 with placebo. TYSABRI decreased the number of relapses by 67% compared with placebo (TYSABRI 0.22 vs placebo 0.67).
ln addition to the clinical trial, TYSABRI was studied in the ongoing TYSABRI Observational Program (TOP). The TOP study is used to further understand the usage of TYSABRI over an extended length of time. We now have over 10 years of interim results. Read below to see what was discovered.
This analysis studied the long-term safety and efficacy of TYSABRI in 6148 patients with relapsing multiple sclerosis. These patients took 300 mg of TYSABRI every 4 weeks.
NO NEW SAFETY CONCERNS WERE IDENTIFIED
SHOWN TO BE EFFECTIVE OVER 10 YEARS
*Compared to average number of relapses in the year before they started TYSABRI (1.99 vs 0.24).